2018 Q2 Form 10-Q Financial Statement
#000114420418044680 Filed on August 14, 2018
Income Statement
| Concept | 2018 Q2 | 2017 Q2 |
|---|---|---|
| Revenue | $123.0M | $81.31M |
| YoY Change | 51.28% | 557.24% |
| Cost Of Revenue | $99.71M | $66.67M |
| YoY Change | 49.55% | 557.97% |
| Gross Profit | $23.30M | $14.64M |
| YoY Change | 59.15% | 553.94% |
| Gross Profit Margin | 18.94% | 18.0% |
| Selling, General & Admin | $10.90M | $4.900M |
| YoY Change | 122.45% | 28.95% |
| % of Gross Profit | 46.78% | 33.47% |
| Research & Development | ||
| YoY Change | ||
| % of Gross Profit | ||
| Depreciation & Amortization | $4.918M | $4.806M |
| YoY Change | 2.33% | 2818.76% |
| % of Gross Profit | 21.11% | 32.83% |
| Operating Expenses | $115.5M | $77.26M |
| YoY Change | 49.53% | 446.59% |
| Operating Profit | $7.150M | $4.056M |
| YoY Change | 76.26% | -330.15% |
| Interest Expense | $110.7K | $575.00 |
| YoY Change | 19149.22% | -78.38% |
| % of Operating Profit | 1.55% | 0.01% |
| Other Income/Expense, Net | $2.240M | -$1.954M |
| YoY Change | -214.62% | -337.85% |
| Pretax Income | $9.389M | $2.102M |
| YoY Change | 346.63% | -323.43% |
| Income Tax | $1.524M | $736.8K |
| % Of Pretax Income | 16.23% | 35.05% |
| Net Earnings | $2.664M | $1.995M |
| YoY Change | 33.56% | -251.66% |
| Net Earnings / Revenue | 2.17% | 2.45% |
| Basic Earnings Per Share | $0.08 | $0.08 |
| Diluted Earnings Per Share | $0.07 | $0.07 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 32.67M shares | 25.07M shares |
| Diluted Shares Outstanding | 37.85M shares | 28.42M shares |
Balance Sheet
| Concept | 2018 Q2 | 2017 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $102.3M | $31.20M |
| YoY Change | 227.88% | 380.0% |
| Cash & Equivalents | $101.1M | $65.79M |
| Short-Term Investments | $1.100M | |
| Other Short-Term Assets | $14.60M | $300.0K |
| YoY Change | 4766.67% | -40.0% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $34.54M | $5.400M |
| Other Receivables | $1.300M | $800.0K |
| Total Short-Term Assets | $152.8M | $37.70M |
| YoY Change | 305.21% | 232.06% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $13.30M | $1.168M |
| YoY Change | 1038.77% | -12.99% |
| Goodwill | $189.6M | $1.622M |
| YoY Change | 11586.09% | |
| Intangibles | $94.93M | $1.823M |
| YoY Change | 5108.5% | -19.29% |
| Long-Term Investments | $23.55M | |
| YoY Change | ||
| Other Assets | $1.516M | $222.0K |
| YoY Change | 582.8% | -68.29% |
| Total Long-Term Assets | $358.2M | $5.599M |
| YoY Change | 6298.06% | -5.85% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $152.8M | $37.70M |
| Total Long-Term Assets | $358.2M | $5.599M |
| Total Assets | $511.0M | $43.30M |
| YoY Change | 1080.12% | 150.28% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $3.633M | $16.20M |
| YoY Change | -77.58% | 276.74% |
| Accrued Expenses | $7.900M | |
| YoY Change | ||
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $300.0K | $4.900M |
| YoY Change | -93.88% | |
| Long-Term Debt Due | $100.0K | $0.00 |
| YoY Change | -100.0% | |
| Total Short-Term Liabilities | $89.12M | $40.84M |
| YoY Change | 118.22% | 488.19% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $13.60M | $5.000M |
| YoY Change | 172.0% | |
| Other Long-Term Liabilities | $9.800M | $700.0K |
| YoY Change | 1300.0% | -75.0% |
| Total Long-Term Liabilities | $51.13M | $5.700M |
| YoY Change | 797.01% | 103.57% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $89.12M | $40.84M |
| Total Long-Term Liabilities | $51.13M | $5.700M |
| Total Liabilities | $140.2M | $46.64M |
| YoY Change | 200.72% | 276.11% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | $7.562M | -$41.27M |
| YoY Change | -118.32% | 37.55% |
| Common Stock | $32.84K | $6.033K |
| YoY Change | 444.36% | 0.58% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $169.6M | -$3.742M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $511.0M | $43.30M |
| YoY Change | 1080.09% | 150.01% |
Cashflow Statement
| Concept | 2018 Q2 | 2017 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | $2.664M | $1.995M |
| YoY Change | 33.56% | -251.66% |
| Depreciation, Depletion And Amortization | $4.918M | $4.806M |
| YoY Change | 2.33% | 2818.76% |
| Cash From Operating Activities | $8.680M | $22.62M |
| YoY Change | -61.63% | -1096.48% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$190.0K | -$40.00K |
| YoY Change | 375.0% | -124.46% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$19.58M | |
| YoY Change | ||
| Cash From Investing Activities | -$19.78M | -$40.00K |
| YoY Change | 49350.0% | -75.0% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -1.490M | -40.00K |
| YoY Change | 3625.0% | -87.88% |
| NET CHANGE | ||
| Cash From Operating Activities | 8.680M | 22.62M |
| Cash From Investing Activities | -19.78M | -40.00K |
| Cash From Financing Activities | -1.490M | -40.00K |
| Net Change In Cash | -12.59M | 22.54M |
| YoY Change | -155.86% | -916.67% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $8.680M | $22.62M |
| Capital Expenditures | -$190.0K | -$40.00K |
| Free Cash Flow | $8.870M | $22.66M |
| YoY Change | -60.86% | -1031.16% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| us-gaap |
Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
|
220192318 | USD | |
| CY2017Q4 | ameh |
Medical Liabilities Current
MedicalLiabilitiesCurrent
|
63972318 | USD |
| CY2016Q4 | ameh |
Medical Liabilities Current
MedicalLiabilitiesCurrent
|
18957465 | USD |
| us-gaap |
Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued
BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
|
6109205 | shares | |
| ameh |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Shares
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares
|
1682110 | shares | |
| ameh |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Shares
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareShares
|
1682110 | shares | |
| CY2018Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3632691 | USD |
| CY2017Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3786381 | USD |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<table style="font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align:top; text-align:justify"><td style="width: 0px; padding: 0px; font-family: "times new roman", times, serif;"></td><td style="width: 0.25in; text-align: left; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td><td style="text-align: justify; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; font-family: "times new roman", times, serif;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of Business</div></div></td></tr></table><div style="clear: both; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 0.5in; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Overview</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">  </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Apollo Medical Holdings, Inc. (“ApolloMed”), entered into an Agreement and Plan of Merger dated as of December 21, 2016 (as amended on March 30, 2017 and October 17, 2017) (the “Merger Agreement”) among ApolloMed, Apollo Acquisition Corp., a California corporation and wholly-owned subsidiary of ApolloMed, Network Medical Management, Inc. (“NMM”), and Kenneth Sim, M.D., not individually but in his capacity as the representative of the shareholders of NMM</div>, pursuant to which ApolloMed effected a merger with NMM<div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> (the “Merger”). The Merger closed and became effective on December 8, 2017 (the “Closing”) (see Note 3). As a result of the Merger, NMM is now a wholly-owned subsidiary of ApolloMed and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed. For accounting purposes, the Merger is treated as a “reverse acquisition,” and NMM is considered the accounting acquirer and ApolloMed is the accounting acquiree. Accordingly, as of the Closing, NMM’s historical results of operations replaced ApolloMed’s historical results of operations for all periods prior to the Merger, and the results of operations of both companies are included in the accompanying consolidated financial statements for all periods following the Merger. Effective as of the Closing, ApolloMed’s board of directors approved a change in ApolloMed’s fiscal year end from March 31 to December 31, to correspond with NMM’s fiscal year end prior to the Merger.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">  </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The combined company, following the Merger, together with its affiliated physician groups and consolidated entities (collectively, the “Company”), is a physician-centric integrated population health management company providing coordinated, outcomes-based medical care in a cost-effective manner and serving patients in California, the majority of whom are covered by private or public insurance </div>provided through <div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Medicare, Medicaid and health maintenance organizations (“HMOs”). A small portion of the Company’s revenue is generated </div><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">from non-insured patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. The Company’s physician network consists of primary care physicians, specialist physicians and hospitalists. The Company operates primarily through the following subsidiaries of ApolloMed: NMM, Apollo Medical Management, Inc. (“AMM”),</div> APA ACO, Inc. (“<div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">APAACO</div>”<div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">) and Apollo Care Connect, Inc. (“Apollo Care Connect”), and their consolidated entities.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">NMM was formed in 1994 as a management service organization (“MSO”) for the purposes of providing management services to medical companies and independent practice associations (“IPAs”). The management services include primarily billing, collection, accounting, administrative, quality assurance, marketing, compliance and education.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">  </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Allied Physicians of California IPA, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (“APC”) was incorporated on August 17, 1992 for the purpose of arranging health care services as an IPA. APC has contracts with various HMOs or licensed health care service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (“PMPM”) that is to be paid to APC. In return, APC arranges for the delivery of health care services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering health care services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On July 1, 1999, APC entered into an amended and restated management and administrative services agreement with NMM for an initial fixed term of 30 years. In accordance with relevant accounting guidance, APC is determined to be a variable interest entity (“VIE”) of the Company as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC’s economic performance through its majority representation on the APC Joint Planning Board; therefore APC is consolidated by NMM. As of June 30, 2018 and December 31, 2017, APC had an ownership interest of 4.87% and 4.95% in ApolloMed, respectively.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Concourse Diagnostic Surgery Center, LLC (“CDSC”) was formed on March 25, 2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California. Its facility is Medicare Certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. During 2011, APC invested $625,000 for a 41.59% ownership interest in CDSC. APC’s ownership percentage in CDSC’s capital stock increased to 43.43% on July 31, 2016. CDSC is consolidated as a VIE by APC as it was determined that APC has a controlling financial interest in CDSC and is the primary beneficiary of CDSC.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">APC also holds a 40% ownership interest in Pacific Ambulatory Surgery Center, LLC (“PASC”), a multi-specialty outpatient surgery center.</div></div><div style="text-align:start;"> </div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">APC-LSMA was formed on October 15, 2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder, Chief Executive and Financial Officer of APC and Co-CEO of ApolloMed, is a nominee shareholder of APC. APC makes all the investment decisions on behalf of APC-LSMA, funds these investments and receives all the distributions from the investments. APC has the obligation to absorb losses or rights to receive benefits from all the investments made by APC-LSMA. APC-LSMA’s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC who is the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA line of business of LaSalle Medical Associates (“LMA”), Pacific Medical Imaging and Oncology Center, Inc. (“PMIOC”), Diagnostic Medical Group (“DMG”) and AHMC International Cancer Center (“ICC”).</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ICC was formed on September 2, 2010 in the state of California. ICC is a Professional Medical California Corporation and has entered into agreements with HMOs, IPAs, medical groups and other purchasers of medical services for the arrangement of services to subscribers or enrollees. On November 15, 2016, APC-LSMA, a holding company of APC, agreed to purchase and acquire from ICC 40% of the aggregate issued and outstanding shares of capital stock of ICC for $400,000 in cash. Certain requirements to complete the investment transaction was completed in August 2017 and effective on October 31, 2017, ICC was determined to be a VIE of APC and is consolidated by APC as it was determined that APC is the primary beneficiary of ICC through its obligation to absorb losses and right to receive benefits that could potentially be significant to ICC. The results of operations of ICC from October 31, 2017 to December 31, 2017 were de minimis.</div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"> </div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Universal Care Acquisition Partners, LLC (“UCAP”), a 100% owned subsidiary of APC, was formed on June 4, 2014, for the purpose of holding an investment in Universal Care, Inc. (“UCI”).</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">APAACO, jointly owned by NMM and AMM, began participating in the next generation accountable care organization model (“NGACO Model”) of the CMS in January 2017. The NGACO Model is a new CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing model. In addition to APAACO, NMM and AMM operated three accountable care organizations (“ACOs”) that participated in the Medicare Shared Savings Program (“MSSP”), with the goal of improving the quality of patient care and outcomes through more efficient and coordinated approach among providers. MSSP revenues are uncertain, and, if such amounts are payable by CMS, they will be paid on an annual basis significantly after the time earned, and are contingent on various factors, including achievement of the minimum savings rate for the relevant period. Such payments are earned and made on an “all or nothing” basis.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In 2012, ApolloMed formed an ACO, ApolloMed Accountable Care Organization, Inc. (“ApolloMed ACO”) to participate in the MSSP.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On November 11, 2015, NMM, ACO Acquisition Corporation, and APCN-ACO, A Medical Professional Corp. (“APCN-ACO”) entered into a reorganization agreement whereby ACO Acquisition Corporation, a newly organized entity in which NMM is its sole shareholder, merged with APCN-ACO, effective on January 8, 2016, resulting in APCN-ACO becoming a wholly owned subsidiary of NMM.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On December 18, 2016, NMM, ACO Acquisition Corporation #2, and Allied Physicians ACO, LLC (“AP-ACO”) entered into a reorganization agreement whereby ACO Acquisition Corporation #2, a newly organized entity in which NMM is its sole shareholder, merged into AP-ACO, effective on December 20, 2016, resulting in AP-ACO becoming a wholly owned subsidiary of NMM.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As the Company is transitioning to the NGACO Model, patients and physicians with the three ACOs have substantially been transferred to APAACO. ApolloMed ACO terminated its MSSP participation agreement with CMS on December 31, 2017. APCN-ACO terminated its MSSP participation agreement with CMS on December 31, 2017. AP-ACO terminated its MSSP participation agreement with CMS on December 31, 2016.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In conjunction with the Merger, ApolloMed sold to APC-LSMA all the issued and outstanding shares of capital stock of Maverick Medical Group, Inc. (“MMG”). MMG has historically been included in the consolidated financial statements filed by ApolloMed.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">  </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">AMM, a wholly-owned subsidiary of ApolloMed, manages affiliated medical groups, which consist of ApolloMed Hospitalists (“AMH”), a hospitalist company, Southern California Heart Centers (“SCHC”), Bay Area Hospitalist Associates (“BAHA”), a medical corporation, ApolloMed Care Clinic (“ACC”) and AKM Medical Group, Inc. (“AKM”). AMH provides hospitalist, intensivist and physician advisor services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. BAHA, ACC and AKM are no longer active to any material extent.</div></div><div style="text-align:start;"> </div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Apollo Care Connect, a wholly-owned subsidiary of ApolloMed, provides a cloud and mobile-based population health management platform that includes digital care plans, a case management module, connectivity with multiple healthcare tracking devices and the ability to integrate with multiple electronic health records to capture clinical data.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ApolloMed also has a controlling interest in Apollo Palliative Services, LLC (“APS”), which owns two Los Angeles-based companies, Best Choice Hospice Care, LLC (“BCHC”) and Holistic Care Home Health Agency, Inc. (“HCHHA”), each of which provides palliative care services.</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Pulmonary Critical Care Management, Inc. (“PCCM”) and Verdugo Medical Management, Inc. (“VMM”), were operated by ApolloMed as physician practice management companies. PCCM and VMM are no longer active to any material extent.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">  </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (including incurred, but not reported (“IBNR”) claims), determination of full-risk and shared-risk revenue and receivable (including constraints, completion factors and the modified retrospective adjustments), income taxes and valuation of share-based compensation. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
| CY2017Q1 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
|
4072222 | USD |
| CY2016Q4 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
|
5338886 | USD |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
8050000 | USD |
| CY2017Q2 | us-gaap |
Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
|
121725058 | USD |
| CY2018Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
37850679 | shares |
| CY2017Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
28417877 | shares |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.15 | ||
| CY2018Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.08 | |
| CY2017Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.08 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.25 | ||
| ameh |
Restricted Cash Acquired From Acquisition
RestrictedCashAcquiredFromAcquisition
|
8000000 | USD | |
| CY2017 | ameh |
Restricted Cash Acquired From Acquisition
RestrictedCashAcquiredFromAcquisition
|
18000000 | USD |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.13 | ||
| CY2018Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.07 | |
| CY2017Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.07 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.22 | ||
| CY2018Q2 | ameh |
Specialty Capitation Payable Current
SpecialtyCapitationPayableCurrent
|
300000 | USD |
| CY2017Q4 | ameh |
Specialty Capitation Payable Current
SpecialtyCapitationPayableCurrent
|
547307 | USD |
| CY2017Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
3648541 | shares |
| CY2018Q2 | us-gaap |
Business Acquisition Share Price
BusinessAcquisitionSharePrice
|
10.00 | |
| ameh |
Medical Liabilities Added From Merger
MedicalLiabilitiesAddedFromMerger
|
0 | USD | |
| CY2017 | ameh |
Medical Liabilities Added From Merger
MedicalLiabilitiesAddedFromMerger
|
39353540 | USD |
| CY2017Q2 | us-gaap |
Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
|
-1755268 | USD |
| us-gaap |
Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
|
-2107249 | USD | |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
14480000 | USD |
| CY2017Q2 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease
|
1394443 | USD |
| us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease
|
127779 | USD | |
| CY2018Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
|
36367555 | USD |
| us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;">Reclassifications</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on the Company’s reported revenue, net income, cash flows or total assets.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
| CY2018Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
|
7261588 | USD |
| CY2017Q2 | us-gaap |
Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
|
5466665 | USD |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
12671000 | USD |
| us-gaap |
Malpractice Loss Contingency Claims Incurred In Period
MalpracticeLossContingencyClaimsIncurredInPeriod
|
34591915 | USD | |
| CY2017 | us-gaap |
Malpractice Loss Contingency Claims Incurred In Period
MalpracticeLossContingencyClaimsIncurredInPeriod
|
23075516 | USD |
| us-gaap |
Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
|
61092050 | USD | |
| ameh |
Number Of Warrants Granted
NumberOfWarrantsGranted
|
0 | shares | |
| CY2018Q2 | ameh |
Subcontractor Ipa Risk Pool Payable
SubcontractorIpaRiskPoolPayable
|
1660366 | USD |
| CY2017Q4 | ameh |
Subcontractor Ipa Risk Pool Payable
SubcontractorIpaRiskPoolPayable
|
1348376 | USD |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
32548662 | shares | |
| CY2018Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
32674459 | shares |
| CY2017Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
25067954 | shares |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
25067954 | shares | |
| dei |
Document Type
DocumentType
|
10-Q | ||
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
37935773 | shares | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
28417877 | shares | |
| CY2018Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
3488386 | USD |
| CY2017Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
3004215 | USD |
| us-gaap |
Equity Fair Value Adjustment
EquityFairValueAdjustment
|
10208000 | USD | |
| ameh |
Number Of Warrants Exercised
NumberOfWarrantsExercised
|
-210625 | shares | |
| us-gaap |
Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
|
104977066 | USD | |
| CY2017 | us-gaap |
Health Care Organization Expenses Net
HealthCareOrganizationExpensesNet
|
121846375 | USD |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
10961000 | USD |
| CY2017Q2 | ameh |
Business Acquisition Proforma Weighted Average Common Shares Outstanding Basic
BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic
|
33601022 | shares |
| ameh |
Business Acquisition Proforma Weighted Average Common Shares Outstanding Basic
BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingBasic
|
33601022 | shares | |
| CY2018Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
|
3211028 | USD |
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| CY2018Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
|
249193 | USD |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
9448000 | USD |
| us-gaap |
Malpractice Loss Contingency Claims Incurred In Prior Periods
MalpracticeLossContingencyClaimsIncurredInPriorPeriods
|
66848868 | USD | |
| CY2017 | us-gaap |
Malpractice Loss Contingency Claims Incurred In Prior Periods
MalpracticeLossContingencyClaimsIncurredInPriorPeriods
|
92476160 | USD |
| ameh |
Class Of Warrant Or Right Cancelled In Period
ClassOfWarrantOrRightCancelledInPeriod
|
-11250 | shares | |
| us-gaap |
Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
|
1392000 | USD | |
| CY2018Q1 | us-gaap |
Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
|
1392000 | USD |
| CY2018Q2 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
708591 | USD |
| CY2017Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
250000 | USD |
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2018-06-30 | ||
| CY2018Q2 | us-gaap |
Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
|
2797859 | USD |
| CY2017Q4 | us-gaap |
Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
|
4343341 | USD |
| CY2018Q2 | us-gaap |
Fresh Start Adjustment Increase Decrease Deferred Income Tax Liabilities Noncurrent
FreshStartAdjustmentIncreaseDecreaseDeferredIncomeTaxLiabilitiesNoncurrent
|
3246098 | USD |
| CY2018Q2 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
3426666 | shares |
| CY2017Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
20117304 | USD |
| ameh |
Adjustments For Medical Liabilities
AdjustmentsForMedicalLiabilities
|
-655266 | USD | |
| CY2017 | ameh |
Adjustments For Medical Liabilities
AdjustmentsForMedicalLiabilities
|
-633386 | USD |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
37323000 | USD |
| CY2017Q2 | us-gaap |
Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
|
-0.05 | |
| us-gaap |
Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
|
-0.06 | ||
| CY2018Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
|
1114332 | USD |
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Risks</div></div></div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company had major payors that contributed the following percentage of net revenue:</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table style="font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;;text-align:left;"><tr style="vertical-align:bottom"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 1pt; width: 74%; vertical-align: bottom;;white-space: nowrap;"> </td><td style="padding: 0in 0in 1pt; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="6" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding: 0in; vertical-align: bottom; width: 11%;;white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">For the Three Months<br/>Ended June 30,</div></div></td><td style="font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td></tr><tr style="vertical-align:bottom"><td style="text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 1pt; width: 74%; vertical-align: bottom;;white-space: nowrap;"> </td><td style="text-align: center; padding: 0in 0in 1pt; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding: 0in; vertical-align: bottom; width: 11%;;white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td><td style="font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td style="font-weight: normal; text-align: center; padding: 0in 0in 1pt; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding: 0in; vertical-align: bottom; width: 11%;;white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></td><td style="font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td></tr><tr style="vertical-align:bottom"><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: "times new roman", times, serif; width: 74%; vertical-align: bottom;;white-space: nowrap;"> </td><td style="text-align: justify; padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="2" style="padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom; width: 11%;;white-space: nowrap;"> </td><td style="padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td style="padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="2" style="padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom; width: 11%;;white-space: nowrap;"> </td><td style="padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 74%; text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;">Payor A</td><td style="width: 1%; text-align: justify; padding: 0in; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 10%; text-align: right; padding: 0in; font-size: 10pt; line-height: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">*</div></td><td style="width: 1%; text-align: left; padding: 0in; font-size: 10pt; line-height: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"> </td><td style="width: 10%; text-align: right; padding: 0in; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;">13.4</td><td style="width: 1%; text-align: left; padding: 0in; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;">%</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: "times new roman", times, serif; width: 74%; background-color: rgb(255, 255, 255); vertical-align: bottom;">Payor B</td><td style="text-align: justify; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; width: 10%; background-color: rgb(255, 255, 255); vertical-align: bottom;">15.4 </td><td style="text-align: left; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;">%</td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"> </td><td style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; width: 10%; background-color: rgb(255, 255, 255); vertical-align: bottom;">17.5</td><td style="text-align: left; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;">%</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: "times new roman", times, serif; width: 74%; background-color: rgb(204, 238, 255); vertical-align: bottom;">Payor C</td><td style="text-align: justify; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="text-align: right; padding: 0in; font-size: 10pt; line-height: 10pt; font-family: "times new roman", times, serif; width: 10%; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">*</div></td><td style="text-align: left; padding: 0in; font-size: 10pt; line-height: 10pt; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"> </td><td style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; width: 10%; background-color: rgb(204, 238, 255); vertical-align: bottom;">12.0</td><td style="text-align: left; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(204, 238, 255); vertical-align: bottom;">%</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: "times new roman", times, serif; width: 74%; background-color: rgb(255, 255, 255); vertical-align: bottom;">Payor D</td><td style="text-align: justify; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; width: 10%; background-color: rgb(255, 255, 255); vertical-align: bottom;">*</td><td style="text-align: left; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;">%</td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"> </td><td style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; width: 10%; background-color: rgb(255, 255, 255); vertical-align: bottom;">12.1</td><td style="text-align: left; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;">%</td></tr></table><div style="clear: both; background: none;"> </div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">   * Less than 10% of total net revenues</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table style="font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;;text-align:left;"><tr style="vertical-align:bottom"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 1pt; width: 74%; vertical-align: bottom;;white-space: nowrap;"> </td><td style="padding: 0in 0in 1pt; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="6" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding: 0in; vertical-align: bottom; width: 11%;;white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">For the Six Months<br/>Ended June 30,</div></div></td><td style="font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td></tr><tr style="vertical-align:bottom"><td style="text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 1pt; width: 74%; vertical-align: bottom;;white-space: nowrap;"> </td><td style="text-align: center; padding: 0in 0in 1pt; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding: 0in; vertical-align: bottom; width: 11%;;white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td><td style="font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td style="font-weight: normal; text-align: center; padding: 0in 0in 1pt; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding: 0in; vertical-align: bottom; width: 11%;;white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></td><td style="font-weight: normal; text-align: center; padding: 0in 0in 0.5pt; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td></tr><tr style="vertical-align:bottom"><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: "times new roman", times, serif; width: 74%; vertical-align: bottom;;white-space: nowrap;"> </td><td style="text-align: justify; padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="2" style="padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom; width: 11%;;white-space: nowrap;"> </td><td style="padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td style="padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="2" style="padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom; width: 11%;;white-space: nowrap;"> </td><td style="padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 74%; text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;">Payor A</td><td style="width: 1%; text-align: justify; padding: 0in; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 10%; text-align: right; padding: 0in; font-size: 10pt; line-height: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">*</div></td><td style="width: 1%; text-align: left; padding: 0in; font-size: 10pt; line-height: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; text-align: left; padding: 0in; font-size: 10pt; line-height: 10pt; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 10%; text-align: right; padding: 0in; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;">13.1</td><td style="width: 1%; text-align: left; padding: 0in; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;">%</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: "times new roman", times, serif; width: 74%; background-color: rgb(255, 255, 255); vertical-align: bottom;">Payor B</td><td style="text-align: justify; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; width: 10%; background-color: rgb(255, 255, 255); vertical-align: bottom;">13.7</td><td style="text-align: left; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;">%</td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="text-align: left; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; width: 10%; background-color: rgb(255, 255, 255); vertical-align: bottom;">20.8</td><td style="text-align: left; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;">%</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: "times new roman", times, serif; width: 74%; background-color: rgb(204, 238, 255); vertical-align: bottom;">Payor C</td><td style="text-align: justify; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="text-align: right; padding: 0in; font-size: 10pt; line-height: 10pt; font-family: "times new roman", times, serif; width: 10%; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">*</div></td><td style="text-align: left; padding: 0in; font-size: 10pt; line-height: 10pt; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">%</div></td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="text-align: left; padding: 0in; font-size: 10pt; line-height: 10pt; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; width: 10%; background-color: rgb(204, 238, 255); vertical-align: bottom;">11.9</td><td style="text-align: left; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(204, 238, 255); vertical-align: bottom;">%</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: "times new roman", times, serif; width: 74%; background-color: rgb(255, 255, 255); vertical-align: bottom;">Payor D</td><td style="text-align: justify; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; width: 10%; background-color: rgb(255, 255, 255); vertical-align: bottom;">10.2</td><td style="text-align: left; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;">%</td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="text-align: left; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; width: 10%; background-color: rgb(255, 255, 255); vertical-align: bottom;">12.4</td><td style="text-align: left; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;">%</td></tr></table><div style="clear: both; background: none;"> </div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">   * Less than 10% of total net revenues</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0px; text-align:justify"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company had major payors that contributed to the following percentage of receivables before the allowance for doubtful accounts:</div></div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"><div style="text-decoration: none; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table style="font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;;text-align:left;"><tr style="vertical-align:bottom"><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 1pt; width: 74%; vertical-align: bottom;;white-space: nowrap;"> </td><td style="text-align: justify; padding: 0in 0in 1pt; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid black; text-align: center; padding: 0in; font-size: 10pt; line-height: 10pt; font-family: "times new roman", times, serif; vertical-align: bottom; width: 11%;;white-space: nowrap;"><div style="font: 10pt "times new roman", times, serif; margin: 0px; text-align: center; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></div></div><div style="font: 10pt "times new roman", times, serif; margin: 0px; text-align: center; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30, 2018</div></div></div></div></td><td style="text-align: center; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; font-family: "times new roman", times, serif; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td style="text-align: center; padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt; font-family: "times new roman", times, serif; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: 1pt solid black; text-align: center; padding: 0in; font-size: 10pt; line-height: 10pt; font-family: "times new roman", times, serif; vertical-align: bottom; width: 11%;;white-space: nowrap;"><div style="font: 10pt "times new roman", times, serif; margin: 0px; text-align: center; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></div></div><div style="font: 10pt "times new roman", times, serif; margin: 0px; text-align: center; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2017</div></div></div></div></td><td style="text-align: center; padding: 0in 0in 0.5pt; font-size: 10pt; line-height: 10pt; font-family: "times new roman", times, serif; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td></tr><tr style="vertical-align:bottom"><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: "times new roman", times, serif; width: 74%; vertical-align: bottom;;white-space: nowrap;"> </td><td style="text-align: justify; padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="2" style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom; width: 11%;;white-space: nowrap;"> </td><td style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td><td colspan="2" style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom; width: 11%;;white-space: nowrap;"> </td><td style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; vertical-align: bottom;;white-space: nowrap;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 74%; text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;">Payor E</td><td style="width: 1%; text-align: justify; padding: 0in; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 10%; text-align: right; padding: 0in; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;">21.6</td><td style="width: 1%; text-align: left; padding: 0in; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;">%</td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 1%; text-align: left; padding: 0in; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="width: 10%; text-align: right; padding: 0in; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;">23.8</td><td style="width: 1%; text-align: left; padding: 0in; font-family: "times new roman", times, serif; background-color: rgb(204, 238, 255); vertical-align: bottom;">%</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: "times new roman", times, serif; width: 74%; background-color: rgb(255, 255, 255); vertical-align: bottom;">Payor F</td><td style="text-align: justify; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background-color: rgb(255, 255, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; width: 10%; background-color: rgb(255, 255, 255); vertical-align: bottom;">32.5 </td><td style="text-align: left; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;">%</td><td style="background-color: rgb(255, 255, 255); width: 1%; vertical-align: bottom; padding: 0in;"><div style="font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="text-align: left; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;"><div style="font-size: 10pt; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; width: 10%; background-color: rgb(255, 255, 255); vertical-align: bottom;">30.5</td><td style="text-align: left; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(255, 255, 255); vertical-align: bottom;">%</td></tr><tr><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; font-family: "times new roman", times, serif; width: 74%; background-color: rgb(204, 238, 255); vertical-align: bottom;">Payor G</td><td style="text-align: justify; padding: 0px; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(204, 238, 255); vertical-align: bottom;"> </td><td style="background-color: rgb(204, 238, 255); width: 1%; text-align: left; vertical-align: bottom; padding: 0px;"> </td><td style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; width: 10%; background-color: rgb(204, 238, 255); vertical-align: bottom;">14.1</td><td style="text-align: left; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(204, 238, 255); vertical-align: bottom;">%</td><td style="background-color: rgb(204, 238, 255); width: 1%; vertical-align: bottom; padding: 0px;"> </td><td style="text-align: left; padding: 0px; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(204, 238, 255); vertical-align: bottom;"> </td><td style="text-align: right; padding: 0in; font-family: "times new roman", times, serif; width: 10%; background-color: rgb(204, 238, 255); vertical-align: bottom;">*</td><td style="text-align: left; padding: 0in; font-family: "times new roman", times, serif; width: 1%; background-color: rgb(204, 238, 255); vertical-align: bottom;">%</td></tr></table><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;"> </div><div style="color: rgb(0, 0, 0); font: 10pt "times new roman", times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-align: justify; background: none;">* Less than 10% of receivables</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2018 | ||
| CY2018Q2 | ameh |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Restricted Cash
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash
|
745220 | USD |
| CY2018Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
101132237 | USD |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
99749199 | USD |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
92933000 | USD |
| CY2018Q2 | ameh |
Medical Liabilities Current
MedicalLiabilitiesCurrent
|
66853335 | USD |
| CY2018Q2 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
708591 | USD |
| CY2017Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
250000 | USD |
| CY2018Q2 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
12587893 | USD |
| CY2017Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
13279620 | USD |
| us-gaap |
Revenues
Revenues
|
247171273 | USD | |
| CY2018Q2 | us-gaap |
Revenues
Revenues
|
123004546 | USD |
| CY2017Q2 | us-gaap |
Revenues
Revenues
|
81311700 | USD |
| us-gaap |
Revenues
Revenues
|
166647762 | USD | |
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.35 | pure |
| CY2018Q1 | ameh |
Allinclusive Populationbased Payments To Be Received
AllinclusivePopulationbasedPaymentsToBeReceived
|
7300000 | USD |
| CY2017Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
9.75 | |
| CY2017Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
24916598 | USD |
| CY2018Q2 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
23545361 | USD |
| CY2017Q4 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
21903524 | USD |
| CY2018Q2 | us-gaap |
Loans Receivable Net
LoansReceivableNet
|
10000000 | USD |
| CY2017Q4 | us-gaap |
Loans Receivable Net
LoansReceivableNet
|
10000000 | USD |
| CY2017Q2 | ameh |
Business Acquisition Proforma Weighted Average Common Shares Outstanding Diluted
BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted
|
33601022 | shares |
| ameh |
Business Acquisition Proforma Weighted Average Common Shares Outstanding Diluted
BusinessAcquisitionProformaWeightedAverageCommonSharesOutstandingDiluted
|
33601022 | shares | |
| CY2018Q2 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
8040870 | USD |
| CY2017Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
18005661 | USD |
| CY2018Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
|
14984000 | USD |
| dei |
Entity Registrant Name
EntityRegistrantName
|
Apollo Medical Holdings, Inc. | ||
| CY2018Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Assets Noncurrent
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssetsNoncurrent
|
2498417 | USD |
| CY2018Q2 | us-gaap |
Assets Held In Trust Current
AssetsHeldInTrustCurrent
|
1294503 | USD |
| CY2017Q2 | ameh |
Finite Lived Intangible Assets Accumulated Amortization Addition
FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition
|
4322476 | USD |
| CY2017Q4 | us-gaap |
Assets Held In Trust Current
AssetsHeldInTrustCurrent
|
2017437 | USD |
| us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
184135500 | USD | |
| CY2018Q2 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
99464892 | USD |
| CY2017Q2 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
66672236 | USD |
| us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
126214808 | USD | |
| CY2018Q2 | us-gaap |
Line Of Credit
LineOfCredit
|
5000000 | USD |
| ameh |
Class Of Warrants Or Right Exercise Price Of Warrants Grant In Period
ClassOfWarrantsOrRightExercisePriceOfWarrantsGrantInPeriod
|
0 | ||
| CY2017 | ameh |
Operating Loss Carryforwards Limitation Rate On Taxable Income
OperatingLossCarryforwardsLimitationRateOnTaxableIncome
|
0.8 | pure |
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001083446 | ||
| CY2017 | ameh |
Increase Decrease In Deferred Tax Assets Due To Change In Enacted Tax Rate
IncreaseDecreaseInDeferredTaxAssetsDueToChangeInEnactedTaxRate
|
6600000 | USD |
| ameh |
Class Of Warrants Or Right Exercise Price Of Warrants Exercised In Period
ClassOfWarrantsOrRightExercisePriceOfWarrantsExercisedInPeriod
|
7.27 | ||
| CY2017Q4 | us-gaap |
Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
|
172129744 | USD |
| CY2017Q2 | us-gaap |
Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
|
-0.05 | |
| us-gaap |
Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
|
-0.06 | ||
| ameh |
Finite Lived Intangible Assets Accumulated Amortization Addition
FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition
|
8606522 | USD | |
| CY2018Q2 | ameh |
Finite Lived Intangible Assets Accumulated Amortization Addition
FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition
|
4211621 | USD |
| ameh |
Finite Lived Intangible Assets Accumulated Amortization Addition
FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition
|
8697317 | USD | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
23207727 | USD | |
| CY2018Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
11471829 | USD |
| CY2017Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5777187 | USD |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
11053762 | USD | |
| CY2018Q2 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
1130967 | USD |
| CY2017Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
1143095 | USD |
| CY2018Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
|
217241 | USD |
| CY2018Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
9976590 | USD | |
| CY2018Q2 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
4918078 | USD |
| CY2017Q2 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
4805979 | USD |
| CY2018Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
32841170 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
32304876 | shares |
| CY2018Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
|
66648574 | USD |
| CY2018Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
34541815 | USD |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
9642330 | USD | |
| ameh |
Class Of Warrants Or Right Exercise Price Of Warrants Forfeited In Period
ClassOfWarrantsOrRightExercisePriceOfWarrantsForfeitedInPeriod
|
0 | ||
| CY2017 | ameh |
Increase Decrease In Deferred Tax Liabilities Due To Change In Enacted Tax Rate
IncreaseDecreaseInDeferredTaxLiabilitiesDueToChangeInEnactedTaxRate
|
16300000 | USD |
| dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | ||
| CY2017 | us-gaap |
Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
|
9700000 | USD |
| CY2018Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
9.91 | |
| CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
1734531 | USD |
| us-gaap |
Operating Expenses
OperatingExpenses
|
217319817 | USD | |
| CY2018Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
115854799 | USD |
| CY2017Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
77255402 | USD |
| us-gaap |
Operating Expenses
OperatingExpenses
|
146910900 | USD | |
| CY2018Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
6622549 | USD |
| CY2017Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3126866 | USD |
| CY2018Q2 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
76476041 | USD |
| CY2017Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
42374500 | USD |
| CY2018Q2 | us-gaap |
Treasury Stock Common Shares
TreasuryStockCommonShares
|
1682110 | shares |
| CY2017Q4 | us-gaap |
Treasury Stock Common Shares
TreasuryStockCommonShares
|
1682110 | shares |
| CY2017Q2 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-795102 | USD |
| us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
1432160 | USD | |
| dei |
Trading Symbol
TradingSymbol
|
AMEH | ||
| CY2018Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
|
8632893 | USD |
| CY2018Q2 | us-gaap |
Assets Current
AssetsCurrent
|
152762941 | USD |
| CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
144159562 | USD |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
29851456 | USD | |
| CY2018Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
7149747 | USD |
| CY2017Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
4056298 | USD |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
19736862 | USD | |
| us-gaap |
Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
|
86394383 | USD | |
| CY2018Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
33522327 | shares |
| CY2018Q2 | ameh |
Extendable Amount On Credit Facility
ExtendableAmountOnCreditFacility
|
8000000 | USD |
| us-gaap |
Profit Loss
ProfitLoss
|
23583248 | USD | |
| us-gaap |
Profit Loss
ProfitLoss
|
13089250 | USD | |
| CY2018Q2 | ameh |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Medical Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesMedicalLiabilities
|
39353540 | USD |
| CY2018Q2 | ameh |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Line Of Credit
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLineOfCredit
|
25000 | USD |
| us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
1641837 | USD | |
| CY2018Q2 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
1669861 | USD |
| CY2018Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
13297168 | USD |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
13814306 | USD |
| ameh |
Percentage Of Managing Responsible Of Health Planship
PercentageOfManagingResponsibleOfHealthPlanship
|
1 | pure | |
| CY2017Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
144476000 | USD |
| CY2016Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
144476000 | USD |
| CY2018Q2 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
94927036 | USD |
| CY2017Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
103533558 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
195684 | USD | |
| CY2018Q2 | us-gaap |
Interest Expense
InterestExpense
|
110683 | USD |
| CY2017Q2 | us-gaap |
Interest Expense
InterestExpense
|
575 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
1386 | USD | |
| CY2018Q2 | ameh |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Convertible Note Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayable
|
5376215 | USD |
| CY2018Q2 | ameh |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Convertible Note Payable To Related Party
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesConvertibleNotePayableToRelatedParty
|
9921938 | USD |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
609634 | USD | |
| CY2018Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
339816 | USD |
| CY2017Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
209492 | USD |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
391777 | USD | |
| CY2018Q2 | us-gaap |
Goodwill
Goodwill
|
189604746 | USD |
| CY2017Q4 | us-gaap |
Goodwill
Goodwill
|
189847202 | USD |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-41782 | USD | |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
0 | USD | |
| CY2018Q2 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
49548964 | USD |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
40942442 | USD |
| ameh |
Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
|
P3Y5M16D | ||
| CY2017 | ameh |
Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
|
P3Y8M26D | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1036326 | USD | |
| CY2018Q2 | us-gaap |
Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
|
278017 | USD |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
28138 | USD | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
642466 | USD | |
| CY2018Q2 | us-gaap |
Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
|
7500000 | USD |
| CY2017Q4 | us-gaap |
Due From Related Parties Noncurrent
DueFromRelatedPartiesNoncurrent
|
5000000 | USD |
| us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
0 | USD | |
| CY2018Q2 | us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
0 | USD |
| CY2017Q2 | us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
-1394443 | USD |
| us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
127779 | USD | |
| CY2018Q2 | us-gaap |
Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value
BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
|
3142000 | USD |
| CY2018Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
|
66451586 | USD |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
428652 | USD | |
| CY2018Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
340659 | USD |
| CY2017Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
26624 | USD |
| us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
-16060 | USD | |
| us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
0 | USD | |
| CY2017Q4 | ameh |
Class Of Warrants Or Right Outstanding Aggregate Intrinsic Value
ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
|
14.25 | USD |
| CY2018Q2 | ameh |
Class Of Warrants Or Right Grant In Period Aggregate Intrinsic Value
ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue
|
0 | USD |
| CY2017Q4 | us-gaap |
Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
|
510391 | USD |
| us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
127779 | USD | |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
2484439 | USD | |
| CY2018Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
2239653 | USD |
| CY2017Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1954004 | USD |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1978468 | USD | |
| CY2018Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
|
196988 | USD |
| CY2018Q2 | ameh |
Investment In Privately Held Entity That Does Not Report Net Asset Value Per Share
InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValuePerShare
|
405000 | USD |
| CY2017Q4 | ameh |
Investment In Privately Held Entity That Does Not Report Net Asset Value Per Share
InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValuePerShare
|
0 | USD |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
32335895 | USD | |
| CY2018Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
9389400 | USD |
| CY2017Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
2102294 | USD |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
21715330 | USD | |
| us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
1641837 | USD | |
| us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
1432160 | USD | |
| CY2018Q2 | ameh |
Class Of Warrants Or Right Exercises In Period Aggregate Intrinsic Value
ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue
|
10.46 | USD |
| CY2018Q2 | ameh |
Class Of Warrants Or Right Forfeitures In Period Aggregate Intrinsic Value
ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue
|
0 | USD |
| us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
706813 | USD | |
| us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-4419701 | USD | |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
8752647 | USD | |
| CY2018Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
1523807 | USD |
| CY2017Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
736835 | USD |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
8626080 | USD | |
| ameh |
Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement
InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement
|
P30Y | ||
| CY2018Q2 | us-gaap |
Profit Loss
ProfitLoss
|
7865593 | USD |
| CY2017Q2 | us-gaap |
Profit Loss
ProfitLoss
|
1365459 | USD |
| CY2018Q2 | ameh |
Class Of Warrants Or Right Outstanding Aggregate Intrinsic Value
ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
|
15.95 | USD |
| CY2018Q2 | ameh |
Investments In Joint Venture
InvestmentsInJointVenture
|
16673840 | USD |
| CY2017Q4 | ameh |
Investments In Joint Venture
InvestmentsInJointVenture
|
0 | USD |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
2824511 | USD | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-14775701 | USD | |
| us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
18758691 | USD | |
| CY2018Q2 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
5201491 | USD |
| CY2017Q2 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-629284 | USD |
| us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
6744846 | USD | |
| CY2018Q2 | us-gaap |
Assets
Assets
|
510977108 | USD |
| CY2017Q4 | us-gaap |
Assets
Assets
|
490635793 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
4824557 | USD | |
| CY2018Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
2664102 | USD |
| CY2017Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
1994743 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
6344404 | USD | |
| CY2018Q2 | us-gaap |
Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
|
5000000 | USD |
| ameh |
Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
|
3495683 | USD | |
| ameh |
Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
|
975914 | USD | |
| CY2018Q2 | us-gaap |
Lines Of Credit Current
LinesOfCreditCurrent
|
0 | USD |
| CY2017Q4 | us-gaap |
Lines Of Credit Current
LinesOfCreditCurrent
|
5025000 | USD |
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
95258 | USD | |
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
86452 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-692000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-1808721 | USD | |
| CY2018Q2 | ameh |
Incentive Payable Current
IncentivePayableCurrent
|
5104074 | USD |
| CY2017Q4 | ameh |
Incentive Payable Current
IncentivePayableCurrent
|
21500000 | USD |
| ameh |
Increase Decrease In Dividends Payable
IncreaseDecreaseInDividendsPayable
|
-617210 | USD | |
| ameh |
Increase Decrease In Dividends Payable
IncreaseDecreaseInDividendsPayable
|
0 | USD | |
| ameh |
Increase Decrease In Incentives Payable
IncreaseDecreaseInIncentivesPayable
|
-16395926 | USD | |
| ameh |
Increase Decrease In Incentives Payable
IncreaseDecreaseInIncentivesPayable
|
-8021645 | USD | |
| CY2018Q2 | ameh |
Fiduciary Accounts Payable Current
FiduciaryAccountsPayableCurrent
|
1294503 | USD |
| CY2017Q4 | ameh |
Fiduciary Accounts Payable Current
FiduciaryAccountsPayableCurrent
|
2017437 | USD |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
13415392 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
24701329 | USD | |
| CY2018Q2 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
2900056 | USD |
| CY2017Q4 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
3198495 | USD |
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
3932 | USD | |
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
1301 | USD | |
| CY2018Q2 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
100228 | USD |
| CY2017Q4 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
98738 | USD |
| us-gaap |
Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
|
0 | USD | |
| us-gaap |
Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
|
200000 | USD | |
| CY2018Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
89118106 | USD |
| CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
109601999 | USD |
| us-gaap |
Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
|
2500000 | USD | |
| us-gaap |
Payments To Fund Longterm Loans To Related Parties
PaymentsToFundLongtermLoansToRelatedParties
|
5000000 | USD | |
| ameh |
Payment Made To Related Party
PaymentMadeToRelatedParty
|
500000 | USD | |
| CY2018Q2 | ameh |
Payment Made To Related Party
PaymentMadeToRelatedParty
|
0 | USD |
| CY2017Q2 | ameh |
Payment Made To Related Party
PaymentMadeToRelatedParty
|
600000 | USD |
| us-gaap |
Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
|
16673840 | USD | |
| us-gaap |
Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
|
0 | USD | |
| CY2017Q2 | us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
0 | USD |
| CY2018Q1 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
16.80 | |
| us-gaap |
Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
|
0 | USD | |
| us-gaap |
Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
|
1000000 | USD | |
| CY2018Q2 | us-gaap |
Long Term Line Of Credit
LongTermLineOfCredit
|
13000000 | USD |
| CY2017Q4 | us-gaap |
Long Term Line Of Credit
LongTermLineOfCredit
|
0 | USD |
| CY2018Q2 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
134800000 | USD |
| CY2018Q2 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
27758780 | USD |
| ameh |
Purchase Of Investments In Privately Held Entity That Does Not Report Net Asset Value Per Share
PurchaseOfInvestmentsInPrivatelyHeldEntityThatDoesNotReportNetAssetValuePerShare
|
405000 | USD | |
| ameh |
Purchase Of Investments In Privately Held Entity That Does Not Report Net Asset Value Per Share
PurchaseOfInvestmentsInPrivatelyHeldEntityThatDoesNotReportNetAssetValuePerShare
|
0 | USD | |
| CY2018Q2 | ameh |
Liability For Unissued Equity Shares Noncurrent
LiabilityForUnissuedEquitySharesNoncurrent
|
1185025 | USD |
| CY2017Q4 | ameh |
Liability For Unissued Equity Shares Noncurrent
LiabilityForUnissuedEquitySharesNoncurrent
|
1185025 | USD |
| ameh |
Payments For Agreement Termination
PaymentsForAgreementTermination
|
400000 | USD | |
| us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
257374 | USD | |
| us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
0 | USD | |
| CY2018Q2 | us-gaap |
Restricted Cash
RestrictedCash
|
8040870 | USD |
| CY2017Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
18005661 | USD |
| CY2018Q2 | ameh |
Dividend Payable Noncurrent
DividendPayableNoncurrent
|
8617210 | USD |
| CY2017Q4 | ameh |
Dividend Payable Noncurrent
DividendPayableNoncurrent
|
18000000 | USD |
| CY2018Q2 | us-gaap |
Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
|
568512 | USD |
| CY2017Q4 | us-gaap |
Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
|
619001 | USD |
| us-gaap |
Increase In Restricted Cash
IncreaseInRestrictedCash
|
8000000 | USD | |
| CY2017 | us-gaap |
Increase In Restricted Cash
IncreaseInRestrictedCash
|
18000000 | USD |
| us-gaap |
Payments Of Dividends
PaymentsOfDividends
|
12000000 | USD | |
| us-gaap |
Payments Of Dividends
PaymentsOfDividends
|
9490632 | USD | |
| CY2018Q2 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
725356 | USD |
| CY2017Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
407953 | USD |
| CY2018Q2 | us-gaap |
Liabilities
Liabilities
|
140247633 | USD |
| CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
154322623 | USD |
| ameh |
Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Exercises In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExercisesInPeriod
|
210625 | shares | |
| CY2018Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
162027547 | USD |
| CY2017Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
158181192 | USD |
| CY2018Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
7561556 | USD |
| ameh |
Warrant Issued During Period Value Stock Options Exercised
WarrantIssuedDuringPeriodValueStockOptionsExercised
|
1500000 | USD | |
| us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
11612590 | USD | |
| us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
9195024 | USD | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
144544 | USD | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
1386 | USD | |
| CY2018Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2017Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| us-gaap |
Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
|
27500 | USD | |
| us-gaap |
Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
|
0 | USD | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
|
37593 | shares |
| ameh |
Equity Method Investment Significant Influence Description
EquityMethodInvestmentSignificantInfluenceDescription
|
Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate. | ||
| us-gaap |
Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
|
8000000 | USD | |
| us-gaap |
Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
|
0 | USD | |
| CY2018Q2 | us-gaap |
Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
|
195914319 | USD |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
631562 | USD |
| us-gaap |
Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
|
48999 | USD | |
| us-gaap |
Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
|
54555 | USD | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-8581636 | USD | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
10861471 | USD | |
| ameh |
Sharebased Compensation Arrangement By Sharebased Payment Award Cashless Options Exercises In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriod
|
60536 | shares | |
| ameh |
Sharebased Compensation Arrangement By Sharebased Payment Award Cashless Options Exercises In Period Net
SharebasedCompensationArrangementBySharebasedPaymentAwardCashlessOptionsExercisesInPeriodNet
|
47576 | shares | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
118500095 | USD |
| CY2016Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
54925712 | USD |
| CY2018Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
32841 | USD |
| CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
32305 | USD |
| CY2018Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
109918459 | USD |
| CY2017Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
65787183 | USD |
| CY2018Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
169621944 | USD |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
159948028 | USD |
| CY2018Q2 | us-gaap |
Minority Interest
MinorityInterest
|
5193212 | USD |
| CY2017Q4 | us-gaap |
Minority Interest
MinorityInterest
|
4235398 | USD |
| CY2018Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
174815156 | USD |
| CY2017Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
164183426 | USD |
| ameh |
Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
|
47 | USD | |
| ameh |
Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
|
0 | USD | |
| CY2018Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
510977108 | USD |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
490635793 | USD |
| ameh |
Deferred Tax Liability Adjustment To Goodwill
DeferredTaxLiabilityAdjustmentToGoodwill
|
1110456 | USD | |
| ameh |
Deferred Tax Liability Adjustment To Goodwill
DeferredTaxLiabilityAdjustmentToGoodwill
|
0 | USD | |
| ameh |
Cumulative Effect Adjustment Included In Accounts Receivable
CumulativeEffectAdjustmentIncludedInAccountsReceivable
|
11600000 | USD | |
| ameh |
Cumulative Effect Adjustment Included In Accounts Receivable
CumulativeEffectAdjustmentIncludedInAccountsReceivable
|
0 | USD | |
| ameh |
Cumulative Effect Adjustment Included In Deferred Tax Liabilities
CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities
|
3246098 | USD | |
| ameh |
Cumulative Effect Adjustment Included In Deferred Tax Liabilities
CumulativeEffectAdjustmentIncludedInDeferredTaxLiabilities
|
0 | USD | |
| ameh |
Purchase Price Adjustment For Acceleration Of Vested Stock Options
PurchasePriceAdjustmentForAccelerationOfVestedStockOptions
|
868000 | USD | |
| ameh |
Purchase Price Adjustment For Acceleration Of Vested Stock Options
PurchasePriceAdjustmentForAccelerationOfVestedStockOptions
|
0 | USD | |
| us-gaap |
Stock Issued1
StockIssued1
|
0 | USD | |
| us-gaap |
Stock Issued1
StockIssued1
|
425025 | USD | |
| CY2017Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
65787183 | USD |
| CY2018Q2 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
745352 | USD |
| CY2017Q2 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
0 | USD |
| CY2017Q2 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
0 | USD |
| CY2017Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
745235 | USD |
| CY2018Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1515664 | USD |
| CY2017Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1632406 | USD |
| ameh |
Increase Decrease In Medical Liabilities
IncreaseDecreaseInMedicalLiabilities
|
2881017 | USD | |
| ameh |
Increase Decrease In Medical Liabilities
IncreaseDecreaseInMedicalLiabilities
|
-437795 | USD | |
| us-gaap |
Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
|
-298439 | USD | |
| us-gaap |
Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
|
3861749 | USD | |
| ameh |
Proceeds From Sale Of Cost Method Investments
ProceedsFromSaleOfCostMethodInvestments
|
0 | USD | |
| ameh |
Proceeds From Sale Of Cost Method Investments
ProceedsFromSaleOfCostMethodInvestments
|
25000 | USD | |
| CY2018Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
202382 | USD |
| CY2017Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
321233 | USD |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
642466 | USD | |
| CY2018Q2 | us-gaap |
Dividends
Dividends
|
10000000 | USD |
| CY2018Q2 | us-gaap |
Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
|
8000000 | USD |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
200000 | USD | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | USD | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
2347329 | USD | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
425025 | USD | |
| CY2018Q2 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
358214167 | USD |
| CY2017Q4 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
346476231 | USD |
| CY2018Q2 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
51129527 | USD |
| CY2017Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
44720624 | USD |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
682712 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
943395 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-20265484 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-4719696 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-1731544 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-9120162 | USD | |
| us-gaap |
Liabilities Assumed1
LiabilitiesAssumed1
|
722934 | USD | |
| us-gaap |
Liabilities Assumed1
LiabilitiesAssumed1
|
2911 | USD | |
| us-gaap |
Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
|
242456 | USD | |
| CY2017 | ameh |
Restricted Cash Acquired From Acquisition
RestrictedCashAcquiredFromAcquisition
|
18000000 | USD |
| us-gaap |
Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
|
671555 | USD | |
| us-gaap |
Goodwill Subsequent Recognition Of Deferred Tax Asset
GoodwillSubsequentRecognitionOfDeferredTaxAsset
|
196445 | USD | |
| ameh |
Goodwill Decrease Merger Transaction Costs
GoodwillDecreaseMergerTransactionCosts
|
914011 | USD | |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
8752647 | USD | |
| CY2018Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
1523807 | USD |
| us-gaap |
Profit Loss
ProfitLoss
|
23583248 | USD | |
| CY2018Q2 | us-gaap |
Profit Loss
ProfitLoss
|
7865593 | USD |
| us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
18758691 | USD | |
| CY2018Q2 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
5201491 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
4824557 | USD | |
| CY2018Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
2664102 | USD |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.15 | ||
| CY2018Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.08 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.13 | ||
| CY2018Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.07 | |
| CY2018Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
34541815 | USD |
| CY2018Q2 | us-gaap |
Assets
Assets
|
510977108 | USD |
| CY2018Q2 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
27758780 | USD |
| CY2018Q2 | us-gaap |
Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
|
195914319 | USD |
| CY2018Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
7561556 | USD |
